Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Other |
Cognitive function |
Cognitive function, evaluated using the Mini-Mental State Examination (MMSE) (0-30 overall score, with scores of 24 and over indicating a normal cognitive function) |
at recruitment (PRE1) |
|
Other |
Cognitive function |
Cognitive function, evaluated using the Montreal Cognitive Assessment (MoCA) (0-30 overall score, with scores of 26 and over indicating a normal cognitive function) |
at recruitment (PRE1) |
|
Other |
Sociodemographic characteristics |
Sociodemographic characteristics, evaluated using a home-made questionnaire recording age, weight, height, living situation, marital status, education, annual income, gynecological and medical history, medication and hormones prescriptions, smoking status, along with the Questionnaire for female Urinary Incontinence Diagnosis (QUID) to determine UI type |
at recruitment (PRE1) |
|
Other |
Signs of vaginal atrophy |
Signs of vaginal atrophy, observed during a gynecological evaluation, using the vaginal atrophy index (VAI) (6-15 overall score, with lower scores indicating more severe symptoms of vaginal atrophy) |
at recruitment (PRE1) |
|
Other |
Pelvic floor muscle function |
Gynecological evaluation of pelvic floor muscle function, using the Laycock's PERFECT score (PERFECT is an acronym with P = power of the pelvic floor muscle contraction, measured with the modified Oxford 6-point scale: 0=no contraction, 1=flicker, 2=weak, 3=moderate, 4=good, and 5=strong; E = endurance of the pelvic floor muscle contraction, measured from 0 to 10 seconds, R = repetitions, measured from 0 to 10 contractions, F = fast contractions, measured as the number of fast maximal contractions over a period of 10 seconds, E = elevation of the posterior vaginal wall during the pelvic floor muscle contraction (yes/no), C = co-contraction of the lower abdominal muscles during the pelvic floor muscle contraction (yes/no), T = timing, with the presence of synchronous involuntary contraction of pelvic floor muscles on coughing (yes/no)) |
at recruitment (PRE1) |
|
Other |
Signs and severity of pelvic prolapse |
Signs and severity of pelvic prolapse, observed during a gynecological evaluation, using the Baden-Walker prolapsus score (0-4 overall score, with higher scores indicating a higher severity) |
at recruitment (PRE1) |
|
Primary |
number of UI episodes |
number of UI episodes, evaluated with a 7-day bladder diary |
at recruitment (PRE1) |
|
Primary |
number of UI episodes |
number of UI episodes, evaluated with a 7-day bladder diary |
just before the intervention (PRE2) |
|
Primary |
number of UI episodes |
number of UI episodes, evaluated with a 7-day bladder diary |
immediately after the 12-week intervention (POST) |
|
Primary |
number of UI episodes |
number of UI episodes, evaluated with a 7-day bladder diary |
6 months after the end of the 12-week intervention (FOLLOW-UP) |
|
Primary |
percentage reduction (%) in the number of UI episodes |
percentage reduction (%) in the number of UI episodes, evaluated with a 7-day bladder diary |
at recruitment (PRE1), just before the intervention (PRE2), immediately after the 12-week intervention (POST), 6 months after the end of the 12-week intervention (FOLLOW-UP) |
|
Secondary |
urinary symptoms and degree to which UI-associated symptoms are troubling or bothersome |
urinary symptoms and degree to which UI-associated symptoms are troubling or bothersome, evaluated using the International Consultation on Incontinence Questionnaire module on UI symptoms (ICIQ-UI) short form (0-21 overall score, with higher scores indicating more sever symptoms) |
at recruitment (PRE1) |
|
Secondary |
urinary symptoms and degree to which UI-associated symptoms are troubling or bothersome |
urinary symptoms and degree to which UI-associated symptoms are troubling or bothersome, evaluated using the International Consultation on Incontinence Questionnaire module on UI symptoms (ICIQ-UI) short form (0-21 overall score, with higher scores indicating more sever symptoms) |
just before the intervention (PRE2) |
|
Secondary |
urinary symptoms and degree to which UI-associated symptoms are troubling or bothersome |
urinary symptoms and degree to which UI-associated symptoms are troubling or bothersome, evaluated using the International Consultation on Incontinence Questionnaire module on UI symptoms (ICIQ-UI) short form (0-21 overall score, with higher scores indicating more sever symptoms) |
immediately after the 12-week intervention (POST) |
|
Secondary |
urinary symptoms and degree to which UI-associated symptoms are troubling or bothersome |
urinary symptoms and degree to which UI-associated symptoms are troubling or bothersome, evaluated using the International Consultation on Incontinence Questionnaire module on UI symptoms (ICIQ-UI) short form (0-21 overall score, with higher scores indicating more sever symptoms) |
6 months after the end of the 12-week intervention (FOLLOW-UP) |
|
Secondary |
Changes in urinary symptoms and degree to which UI-associated symptoms are troubling or bothersome |
urinary symptoms and degree to which UI-associated symptoms are troubling or bothersome, evaluated using the International Consultation on Incontinence Questionnaire module on UI symptoms (ICIQ-UI) short form (0-21 overall score, with higher scores indicating more sever symptoms) |
at recruitment (PRE1), just before the intervention (PRE2), immediately after the 12-week intervention (POST), 6 months after the end of the 12-week intervention (FOLLOW-UP) |
|
Secondary |
bladder, bowel, pelvic organ prolapse and sexual function symptoms and degree to which these symptoms are troubling or bothersome |
bladder, bowel, pelvic organ prolapse and sexual function symptoms and degree to which these symptoms are troubling or bothersome, evaluated using the Australian Pelvic Floor Questionnaire (APFQ) (0-45 score for bladder symptoms, 0-34 score for bowel symptoms, 0-15 score for pelvic organ prolapse symptoms, and 0-21 score for sexual function symptoms, with higher scores indicating more severe symptoms) |
at recruitment (PRE1) |
|
Secondary |
bladder, bowel, pelvic organ prolapse and sexual function symptoms and degree to which these symptoms are troubling or bothersome |
bladder, bowel, pelvic organ prolapse and sexual function symptoms and degree to which these symptoms are troubling or bothersome, evaluated using the Australian Pelvic Floor Questionnaire (APFQ) (0-45 score for bladder symptoms, 0-34 score for bowel symptoms, 0-15 score for pelvic organ prolapse symptoms, and 0-21 score for sexual function symptoms, with higher scores indicating more severe symptoms) |
just before the intervention (PRE2) |
|
Secondary |
bladder, bowel, pelvic organ prolapse and sexual function symptoms and degree to which these symptoms are troubling or bothersome |
bladder, bowel, pelvic organ prolapse and sexual function symptoms and degree to which these symptoms are troubling or bothersome, evaluated using the Australian Pelvic Floor Questionnaire (APFQ) (0-45 score for bladder symptoms, 0-34 score for bowel symptoms, 0-15 score for pelvic organ prolapse symptoms, and 0-21 score for sexual function symptoms, with higher scores indicating more severe symptoms) |
immediately after the 12-week intervention (POST) |
|
Secondary |
bladder, bowel, pelvic organ prolapse and sexual function symptoms and degree to which these symptoms are troubling or bothersome |
bladder, bowel, pelvic organ prolapse and sexual function symptoms and degree to which these symptoms are troubling or bothersome, evaluated using the Australian Pelvic Floor Questionnaire (APFQ) (0-45 score for bladder symptoms, 0-34 score for bowel symptoms, 0-15 score for pelvic organ prolapse symptoms, and 0-21 score for sexual function symptoms, with higher scores indicating more severe symptoms) |
6 months after the end of the 12-week intervention (FOLLOW-UP) |
|
Secondary |
Changes in bladder, bowel, pelvic organ prolapse and sexual function symptoms and degree to which these symptoms are troubling or bothersome |
bladder, bowel, pelvic organ prolapse and sexual function symptoms and degree to which these symptoms are troubling or bothersome, evaluated using the Australian Pelvic Floor Questionnaire (APFQ) (0-45 score for bladder symptoms, 0-34 score for bowel symptoms, 0-15 score for pelvic organ prolapse symptoms, and 0-21 score for sexual function symptoms, with higher scores indicating more severe symptoms) |
at recruitment (PRE1), just before the intervention (PRE2), immediately after the 12-week intervention (POST), 6 months after the end of the 12-week intervention (FOLLOW-UP) |
|
Secondary |
UI-related quality of life |
UI-related quality of life, evaluated using the International Consultation on Incontinence Questionnaire module on Lower Urinary Tract Symptoms quality of life (ICIQ-LUTS QoL) (19-76 overall score with greater values indicating increased impact on quality of life) |
at recruitment (PRE1) |
|
Secondary |
UI-related quality of life |
UI-related quality of life, evaluated using the International Consultation on Incontinence Questionnaire module on Lower Urinary Tract Symptoms quality of life (ICIQ-LUTS QoL) (19-76 overall score with greater values indicating increased impact on quality of life) |
just before the intervention (PRE2) |
|
Secondary |
UI-related quality of life |
UI-related quality of life, evaluated using the International Consultation on Incontinence Questionnaire module on Lower Urinary Tract Symptoms quality of life (ICIQ-LUTS QoL) (19-76 overall score with greater values indicating increased impact on quality of life) |
immediately after the 12-week intervention (POST) |
|
Secondary |
UI-related quality of life |
UI-related quality of life, evaluated using the International Consultation on Incontinence Questionnaire module on Lower Urinary Tract Symptoms quality of life (ICIQ-LUTS QoL) (19-76 overall score with greater values indicating increased impact on quality of life) |
6 months after the end of the 12-week intervention (FOLLOW-UP) |
|
Secondary |
Changes in UI-related quality of life |
UI-related quality of life, evaluated using the International Consultation on Incontinence Questionnaire module on Lower Urinary Tract Symptoms quality of life (ICIQ-LUTS QoL) (19-76 overall score with greater values indicating increased impact on quality of life) |
at recruitment (PRE1), just before the intervention (PRE2), immediately after the 12-week intervention (POST), 6 months after the end of the 12-week intervention (FOLLOW-UP) |
|
Secondary |
UI-associated costs |
UI-associated costs, using the adapted Dowell-Bryant Incontinence Cost Index (DBICI) questionnaire |
at recruitment (PRE1) |
|
Secondary |
UI-associated costs |
UI-associated costs, using the adapted Dowell-Bryant Incontinence Cost Index (DBICI) questionnaire |
immediately after the 12-week intervention (POST) |
|
Secondary |
UI-associated costs |
UI-associated costs, using the adapted Dowell-Bryant Incontinence Cost Index (DBICI) questionnaire |
6 months after the end of the 12-week intervention (FOLLOW-UP) |
|
Secondary |
technology self-efficacy |
technology self-efficacy, evaluated using the Online Technologies Self-efficacy Scale (OTSES) questionnaire (30-120 overall score, with higher scores indicating lower level of technology self-efficacy) |
at recruitment (PRE1) |
|
Secondary |
technology self-efficacy |
technology self-efficacy, evaluated using the Online Technologies Self-efficacy Scale (OTSES) questionnaire (30-120 overall score, with higher scores indicating lower level of technology self-efficacy) |
immediately after the 12-week intervention (POST) |
|
Secondary |
technology self-efficacy |
technology self-efficacy, evaluated using the Online Technologies Self-efficacy Scale (OTSES) questionnaire (30-120 overall score, with higher scores indicating lower level of technology self-efficacy) |
6 months after the end of the 12-week intervention (FOLLOW-UP) |
|
Secondary |
UI related self-efficacy |
UI related self-efficacy, evaluated using the geriatric self-efficacy scale (GES) (0-120 overall score, with higher scores indicating higher level of self-efficacy related to urinary incontinence) |
at recruitment (PRE1) |
|
Secondary |
UI related self-efficacy |
UI related self-efficacy, evaluated using the geriatric self-efficacy scale (GES) (0-120 overall score, with higher scores indicating higher level of self-efficacy related to urinary incontinence) |
immediately after the 12-week intervention (POST) |
|
Secondary |
UI related self-efficacy |
UI related self-efficacy, evaluated using the geriatric self-efficacy scale (GES) (0-120 overall score, with higher scores indicating higher level of self-efficacy related to urinary incontinence) |
6 months after the end of the 12-week intervention (FOLLOW-UP) |
|
Secondary |
Pelvic floor muscles related self-efficacy |
Pelvic floor muscles related self-efficacy, evaluated using the Broome's self-efficacy scale (14 items with responses ranging 0-100 for part A and 9 items with responses ranging 0-100 for part B; an overall mean self-efficacy score is calculated, also ranging 0-100) |
at recruitment (PRE1) |
|
Secondary |
Pelvic floor muscles related self-efficacy |
Pelvic floor muscles related self-efficacy, evaluated using the Broome's self-efficacy scale (14 items with responses ranging 0-100 for part A and 9 items with responses ranging 0-100 for part B; an overall mean self-efficacy score is calculated, also ranging 0-100) |
immediately after the 12-week intervention (POST) |
|
Secondary |
Pelvic floor muscles related self-efficacy |
Pelvic floor muscles related self-efficacy, evaluated using the Broome's self-efficacy scale (14 items with responses ranging 0-100 for part A and 9 items with responses ranging 0-100 for part B; an overall mean self-efficacy score is calculated, also ranging 0-100) |
6 months after the end of the 12-week intervention (FOLLOW-UP) |
|
Secondary |
Vaginal atrophy symptoms |
Vaginal atrophy symptoms, evaluated using the Atrophy Symptom Questionnaire (ASQ) (0-15 overall score, with higher scores indicating higher severity of vaginal atrophy symptoms) |
at recruitment (PRE1) |
|
Secondary |
Vaginal atrophy symptoms |
Vaginal atrophy symptoms, evaluated using the Atrophy Symptom Questionnaire (ASQ) (0-15 overall score, with higher scores indicating higher severity of vaginal atrophy symptoms) |
immediately after the 12-week intervention (POST) |
|
Secondary |
Vaginal atrophy symptoms |
Vaginal atrophy symptoms, evaluated using the Atrophy Symptom Questionnaire (ASQ) (0-15 overall score, with higher scores indicating higher severity of vaginal atrophy symptoms) |
6 months after the end of the 12-week intervention (FOLLOW-UP) |
|
Secondary |
Patient reported improvement and satisfaction |
Patient reported improvement and satisfaction, evaluated using the patient global impression of improvement (PGI-I) index, a single-item tool to capture perceived satisfaction with treatment: "satisfied" (does not need other treatments); "unsatisfied" (would like another treatment for UI) |
immediately after the 12-week intervention (POST) |
|
Secondary |
Patient reported improvement and satisfaction |
Patient reported improvement and satisfaction, evaluated using the patient global impression of improvement (PGI-I) index, a single-item tool to capture perceived satisfaction with treatment: "satisfied" (does not need other treatments); "unsatisfied" (would like another treatment for UI) |
6 months after the end of the 12-week intervention (FOLLOW-UP) |
|
Secondary |
Feasibility/Acceptability (reach) |
Reach aspect of feasibility/acceptability, evaluated using attendance to weekly sessions |
through intervention completion, for 12 weeks |
|
Secondary |
Feasibility/Acceptability (fidelity) |
Fidelity aspect of feasibility/acceptability, evaluated using the integrity of the GROUP program elements delivered by the physiotherapist during each session (checklist) |
through intervention completion, for 12 weeks |
|
Secondary |
Feasibility/Acceptability (dose) |
Dose aspect feasibility/acceptability, evaluated using adherence to home exercises (exercises journal) |
through intervention completion, for 12 weeks |
|
Secondary |
Feasibility/Acceptability (perceived usability of the technology) |
Perceived usability of the technology from the patients' experience as an aspect of feasibility/acceptability, evaluated using the System Usability Scale (SUS) (0-100 overall score, with higher scores indicating a higher usability) |
immediately after the 12-week intervention (POST) |
|
Secondary |
Feasibility/Acceptability (perceived usability of the technology) |
Perceived usability of the technology from the patients' experience as an aspect of feasibility/acceptability, evaluated using the System Usability Scale (SUS) (0-100 overall score, with higher scores indicating a higher usability) |
6 months after the end of the 12-week intervention (FOLLOW-UP) |
|
Secondary |
Potential challenges and satisfaction with the program from the patients' perspective |
Potential challenges and satisfaction with the program from the patients' perspective, evaluated during focus groups or interviews using an interview guide developed from the seven dimensions of the Theoretical Framework of Acceptability (TFA), three of the five Consolidated Framework for Implementation Research (CFIR) domains and additional open-ended questions on satisfaction |
immediately after the intervention (POST) |
|